{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:56:24Z","timestamp":1762674984631,"version":"build-2065373602"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"22","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Clozapine is primarily metabolized by cytochrome P450 (CYP) 1A2 and to a lesser extent by CYP2C19, CYP2D6, and CYP3A4. The global pandemic of coronavirus disease 2019 (COVID-19) and use of nirmatrelvir\/ritonavir brought forth new challenges for those caring for patients prescribed clozapine. Prescribing information describes a consideration for a clozapine dose reduction while monitoring for adverse reactions when clozapine is used with nirmatrelvir\/ritonavir. Other drug information resources consider the combination a contraindication. A case is reported in which therapeutic drug monitoring demonstrated a lack of interaction between clozapine and nirmatrelvir\/ritonavir. The complexities of infection-associated clozapine toxicity are discussed and a review is provided of CYP3A4 drug and gene interactions with clozapine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A 75-year-old woman with schizophrenia, prescribed clozapine 200\u2005mg by mouth at bedtime, was initiated on nirmatrelvir\/ritonavir after developing a mild COVID-19 infection. Two days later, the patient was brought to the emergency department after an unwitnessed fall. Clozapine toxicity was included in the differential diagnosis, although no other signs or symptoms of elevated clozapine levels were present. Nirmatrelvir\/ritonavir was discontinued. Clozapine was withheld for 1 day while a clozapine level was pending, but this measurement revealed no interaction when compared to a baseline level of clozapine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although there are hypothetical concerns when initiating a CYP3A4 inhibitor with concomitant clozapine, the information derived from this case does not clearly support an interaction with the addition of nirmatrelvir\/ritonavir during mild COVID-19 infection. It is important to understand the risks of withholding clozapine, although fortunately no psychiatric concerns developed. In reviewing the literature, CYP3A4 inhibitors or genetic polymorphisms seem to have a minimal impact on clozapine levels, although clinical monitoring is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf156","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T07:41:10Z","timestamp":1750146070000},"page":"1228-1237","source":"Crossref","is-referenced-by-count":0,"title":["Clozapine and nirmatrelvir\/ritonavir coadministration without apparent interaction in a patient with mild COVID-19 infection: A case with review of other clozapine-related CYP3A4 interactions"],"prefix":"10.1093","volume":"82","author":[{"given":"Jonathan G","family":"Leung","sequence":"first","affiliation":[{"name":"Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra J","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa K","family":"Kuhn","sequence":"additional","affiliation":[{"name":"University of Wisconsin\u2013Madison School of Pharmacy , Madison, WI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"6","key":"2025110902543441800_zxaf156-B1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JCP.0000000000001606","article-title":"The modernization of clozapine: a recapitulation of the past in the United States and the view forward","volume":"42","author":"Leung","year":"2022","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"2025110902543441800_zxaf156-B2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/FPC.0000000000000347","article-title":"PharmGKB summary: clozapine pathway, pharmacokinetics","volume":"28","author":"Thorn","year":"2018","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"2025110902543441800_zxaf156-B3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/s0731-7085(01)00410-1","article-title":"Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography\/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients","volume":"26","author":"Aravagiri","year":"2001","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"2025110902543441800_zxaf156-B4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/138920007780655469","article-title":"CYP-mediated clozapine interactions: how predictable are they?","volume":"8","author":"Chetty","year":"2007","journal-title":"Curr Drug Metab"},{"issue":"8","key":"2025110902543441800_zxaf156-B5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1177\/00912700122010717","article-title":"Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations","volume":"41","author":"Olesen","year":"2001","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2025110902543441800_zxaf156-B6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1176\/appi.ajp.2020.20071039","article-title":"Clozapine intoxication in COVID-19","volume":"178","author":"Tio","year":"2021","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2025110902543441800_zxaf156-B7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.rpsmen.2022.06.010","article-title":"A Covid-19 outbreak in a Spanish long-term psychiatric hospital led to infections in 6 clozapine patients: elevations in their plasma clozapine levels","volume":"15","author":"Arrojo-Romero","year":"2022","journal-title":"Rev Psiquiatr Salud Ment"},{"issue":"2","key":"2025110902543441800_zxaf156-B8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/JCP.0000000000001828","article-title":"Question: how should I monitor and adjust the clozapine dose for my patients who develop COVID and could benefit from nirmatrelvir\/ritonavir?","volume":"44","author":"de Leon","year":"2024","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"2025110902543441800_zxaf156-B9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/ph13120439","article-title":"Clinically relevant interactions between atypical antipsychotics and anti-infective agents","volume":"13","author":"Spina","year":"2020","journal-title":"Pharmaceuticals"},{"key":"2025110902543441800_zxaf156-B10","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241233842","article-title":"Alert prescribing of clozapine: a comparison of five drug-drug interaction sources","volume":"15","author":"Govaerts","year":"2024","journal-title":"Ther Adv Drug Saf"},{"issue":"4","key":"2025110902543441800_zxaf156-B11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"5","key":"2025110902543441800_zxaf156-B12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4088\/jcp.v62n0512d","article-title":"Increase in plasma levels of clozapine and norclozapine after administration of nefazodone","volume":"62","author":"Khan","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2025110902543441800_zxaf156-B13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s002280050440","article-title":"Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole","volume":"54","author":"Raaska","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"2025110902543441800_zxaf156-B14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00004850-199905030-00007","article-title":"The effect of nefazodone on clozapine plasma concentrations","volume":"14","author":"Taylor","year":"1999","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"2025110902543441800_zxaf156-B15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/schbul\/sbab103","article-title":"Reducing the risk of withdrawal symptoms and relapse following clozapine discontinuation\u2014is it feasible to develop evidence-based guidelines?","volume":"48","author":"Blackman","year":"2022","journal-title":"Schizophr Bull"},{"issue":"6","key":"2025110902543441800_zxaf156-B16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/FTD.0000000000001233","article-title":"Making clozapine therapeutic drug monitoring essential for optimal patient care: letter to the editor","volume":"46","author":"Leung","year":"2024","journal-title":"Ther Drug Monit"},{"issue":"2","key":"2025110902543441800_zxaf156-B17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/FTD.0000000000001188","article-title":"A short turnaround of clozapine blood level results within 6\u2005hours is essential for effective management of severely ill persons with treatment-resistant schizophrenia","volume":"46","author":"Vincent","year":"2024","journal-title":"Ther Drug Monit"},{"issue":"6","key":"2025110902543441800_zxaf156-B18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/17425255.2022.2106214","article-title":"Drug-drug interactions between psychotropic medications and oral contraceptives","volume":"18","author":"Schoretsanitis","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"2025110902543441800_zxaf156-B19","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1176\/appi.psy.50.6.626","article-title":"Clozapine use in HIV-infected schizophrenia patients: a case-based discussion and review","volume":"50","author":"Nejad","year":"2009","journal-title":"Psychosomatics"},{"issue":"6","key":"2025110902543441800_zxaf156-B20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/HRP.0000000000000120","article-title":"Consideration of clozapine and gender-affirming medical care for an HIV-positive person with schizophrenia and fluctuating gender identity","volume":"24","author":"Gerken","year":"2016","journal-title":"Harv Rev Psychiatry"},{"issue":"12","key":"2025110902543441800_zxaf156-B21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/2045125318804499","article-title":"Clozapine, HIV and neutropenia: a case report","volume":"8","author":"Whiskey","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"issue":"10","key":"2025110902543441800_zxaf156-B22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.4088\/jcp.v62n1010","article-title":"Repeated ingestion of grapefruit juice does not alter clozapine\u2019s steady-state plasma levels, effectiveness, and tolerability","volume":"62","author":"Lane","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"3-4","key":"2025110902543441800_zxaf156-B23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1515\/dmdi.2001.18.3-4.263","article-title":"Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo","volume":"18","author":"Lane","year":"2001","journal-title":"Drug Metabol Drug Interact"},{"issue":"4","key":"2025110902543441800_zxaf156-B24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s002280000126","article-title":"Plasma levels of clozapine and desmethylclozapine are unaffected by concomitant ingestion of grapefruit juice","volume":"56","author":"Vandel","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"2025110902543441800_zxaf156-B25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1081\/clt-100100939","article-title":"Monitoring of clozapine and norclozapine plasma concentration-time curves in acute overdose","volume":"38","author":"Renwick","year":"2000","journal-title":"J Toxicol Clin Toxicol"},{"issue":"12","key":"2025110902543441800_zxaf156-B26","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1176\/ajp.151.12.1840b","article-title":"Seizure following addition of erythromycin to clozapine treatment","volume":"151","author":"Funderburg","year":"1994","journal-title":"Am J Psychiatry"},{"issue":"6","key":"2025110902543441800_zxaf156-B27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archinte.1996.00440060103013","article-title":"Erythromycin-induced clozapine toxic reaction","volume":"156","author":"Cohen","year":"1996","journal-title":"Arch Intern Med"},{"issue":"3","key":"2025110902543441800_zxaf156-B28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s002280050621","article-title":"Absence of interaction between erythromycin and a single dose of clozapine","volume":"55","author":"H\u00e4gg","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"2025110902543441800_zxaf156-B29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13256-015-0547-2","article-title":"Clozapine toxicity due to a multiple drug interaction: a case report","volume":"9","author":"Cadeddu","year":"2015","journal-title":"J Med Case Rep"},{"issue":"1","key":"2025110902543441800_zxaf156-B30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/bcp.15889","article-title":"Effect of lemborexant on pharmacokinetics of clozapine: a potential drug-drug interaction mediated by time-dependent inhibition of CYP3A4","volume":"90","author":"Watanabe","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2025110902543441800_zxaf156-B31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/JCP.0000000000001808","article-title":"Concomitant use of clozapine and suvorexant associated with doubling of clozapine plasma levels: a case report","volume":"44","author":"Kikuchi","year":"2024","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"2025110902543441800_zxaf156-B32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/JCP.0000000000001817","article-title":"Clozapine-associated myocarditis in a patient with schizophrenia taking lemborexant: a case report","volume":"44","author":"Mori","year":"2024","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"2025110902543441800_zxaf156-B33","first-page":"21","article-title":"A case report of cimetidine-induced clozapine toxicity","volume":"52","author":"Szymanski","year":"1991","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2025110902543441800_zxaf156-B34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1176\/appi.psy.48.2.170","article-title":"Clozapine case series","volume":"48","author":"Sandson","year":"2007","journal-title":"Psychosomatics"},{"issue":"3","key":"2025110902543441800_zxaf156-B35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1176\/appi.psy.49.3.255","article-title":"Elevated clozapine serum level after treatment with amiodarone","volume":"49","author":"Stevens","year":"2008","journal-title":"Psychosomatics"},{"issue":"5","key":"2025110902543441800_zxaf156-B36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jaclp.2024.06.001","article-title":"Concurrent clozapine and amiodarone treatment","volume":"65","author":"Kilciksiz","year":"2024","journal-title":"J Acad Consult Liaison Psychiatry"},{"key":"2025110902543441800_zxaf156-B37"},{"author":"Lexicomp","key":"2025110902543441800_zxaf156-B38"},{"key":"2025110902543441800_zxaf156-B39","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211030844","article-title":"Possible pharmacogenetic factors in clozapine treatment failure: a case report","volume":"11","author":"Whiskey","year":"2021","journal-title":"Ther Adv Psychopharmacol"},{"key":"2025110902543441800_zxaf156-B40","doi-asserted-by":"publisher","first-page":"102126","DOI":"10.1016\/j.ajp.2020.102126","article-title":"Unusually high serum levels of clozapine associated with genetic polymorphism of CYP3A enzymes","volume":"57","author":"John","year":"2021","journal-title":"Asian J Psychiatr"},{"issue":"4","key":"2025110902543441800_zxaf156-B41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","article-title":"ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine","volume":"29","author":"Jaquenoud Sirot","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"2025110902543441800_zxaf156-B42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/JCP.0b013e3181f03e30","article-title":"The participation of cytochrome P450 3A4 in clozapine biotransformation is detected in people with schizophrenia by high-throughput in vivo phenotyping","volume":"30","author":"Ghassabian","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"2025110902543441800_zxaf156-B43","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/ijnp\/pyx019","article-title":"Potential role of patients\u2019 CYP3A-status in clozapine pharmacokinetics","volume":"20","author":"T\u00f3th","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"2025110902543441800_zxaf156-B44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/JCP.0b013e31825ac35c","article-title":"Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response","volume":"32","author":"Lee","year":"2012","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"2025110902543441800_zxaf156-B45","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2217\/pgs-2019-0037","article-title":"High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: a case report","volume":"20","author":"Mian","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"1","key":"2025110902543441800_zxaf156-B46","doi-asserted-by":"publisher","first-page":"21283","DOI":"10.1038\/s41598-020-78474-0","article-title":"Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia","volume":"10","author":"Menus","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"2025110902543441800_zxaf156-B47","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1177\/02698811231199104","article-title":"Predicting clozapine dose required to achieve a therapeutic plasma concentration\u2014a comparison of a population algorithm and three algorithms based on gene variant models","volume":"37","author":"Taylor","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"17","key":"2025110902543441800_zxaf156-B48","doi-asserted-by":"publisher","first-page":"9866","DOI":"10.3390\/ijms23179866","article-title":"The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?","volume":"23","author":"Loos","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2025110902543441800_zxaf156-B49","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1124\/mol.114.094862","article-title":"Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4","volume":"86","author":"Rock","year":"2014","journal-title":"Mol Pharmacol"},{"issue":"5","key":"2025110902543441800_zxaf156-B50","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2025110902543441800_zxaf156-B51","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1365-2125.2009.03545.x","article-title":"Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase","volume":"68","author":"Greenblatt","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2025110902543441800_zxaf156-B52","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/j.1875-9114.1991.tb02628.x","article-title":"Clozapine","volume":"11","author":"Jann","year":"1991","journal-title":"Pharmacotherapy"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf156\/63513416\/zxaf156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/22\/1228\/63513416\/zxaf156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/22\/1228\/63513416\/zxaf156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:54:39Z","timestamp":1762674879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/22\/1228\/8166553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":52,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,6,18]]},"published-print":{"date-parts":[[2025,11,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf156","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2025,11,15]]},"published":{"date-parts":[[2025,6,18]]}}}